Skip to main content
Gene therapy for long-term treatment of Pompe disease

Gene therapy for long-term treatment of Pompe disease

Unmet Need Pompe disease is a rare heritable disorder impacting heart and skeletal muscle function with an estimated incidence rate of 1 in 40,000 births in the US. Of these affected births, a third take…

Read More

Gene therapy for ATP1A3-Related Neurologic Disorders

Gene therapy for ATP1A3-Related Neurologic Disorders

Unmet Need Children with Alternating Hemiplegia of Childhood can have episodes of temporary paralysis, dystonia, and severe behavioral problems. The prevalence of AHC is estimated to be 1 in one million to 1 out of…

Read More

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

Unmet Need Beta-arrestins are a highly conserved family of cytosolic adaptor proteins that contribute to a multitude of physiological functions through a canonical interaction with various G protein-coupled receptors (GPCRs). Through agonist binding to GPCRs,…

Read More

Muscle mass influences upon response to therapy

Muscle mass influences upon response to therapy

Duke University is seeking a company interested in commercializing a drug treatment method for enhancing lysosomal storage disease therapy by modulating cell surface receptor expression. Lysosmal storage diseases (LSDs), including Pompe disease, Gaucher disease, Farby…

Read More

A method of screening and monitoring glycogen storage diseases with a single biomarker

A method of screening and monitoring glycogen storage diseases with a single biomarker

Unmet Need Glycogen storage disease type I (GSD I) is an autosomal recessive inherited disorder of carbohydrate metabolism associated with life threatening fasting hypoglycemia, and significant morbidity and mortality. Currently, the standard of care therapy…

Read More

Method for treating glycogen storage disease

Method for treating glycogen storage disease

The present disclosure is directed to methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by…

Read More

MEK inhibitors as therapeutic agents and diagnostic tools for hemoglobinopathies, including thalassemia

MEK inhibitors as therapeutic agents and diagnostic tools for hemoglobinopathies, including thalassemia

Value Proposition Patients with sickle cell disease experience acute vaso-occlusive “crises”, which lead to significant pain, multiple organ damage, and eventually organ failure. Such crises are caused largely by their abnormal sickle red blood cells,…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us